- CSR Summary Not Yet Available
- NCT01314118
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameAbiraterone acetateProduct NameZYTIGA®Therapeutic AreaCancers and Other NeoplasmsEnrollment131% FemaleN/A% White82.4%
Product ClassHormonesSponsor Protocol Number212082PCR2005Data PartnerJohnson & JohnsonCondition StudiedNeoplasms, ProstaticMean/Median Age (Years)72
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Additional Information
Please note: only primary analysis data (completed in 2013) are available for this study.
Approved Data Requests Associated with this Trial
- 2022-5125 : Risk of therapy-related adverse events in men on abiraterone or enzalutamide, a meta-analysis of clinical trial data
- 2022-4942 : External Validation of a Prognostic Model of Metastasis-Free Survival In Men with Nonmetastatic Castration-Resistant Prostate Cancer
- 2020-4189 : Design and validation of an external control arm using prior clinical trials and real-world data
- 2019-3999 : Psychiatric Symptoms as Adverse Events of Abiraterone / Prednisolone Therapy: Systematic Review and Meta-Analysis
- 2019-3886 : The relative efficacy and safety of enzalutamide, apalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer